目的 探讨肝苏片联合聚乙二醇化干扰素α-2a注射液治疗慢性乙型肝炎临床效果。方法 选取2014年6月—2016年6月在乐东黎族自治县中医院治疗的乙型病毒性肝炎患者60例作为研究对象，所有患者随机分为对照组和治疗组，每组各30例。对照组患者臀部皮下注射聚乙二醇化干扰素α-2a注射液，180 μg/次，1次/周。治疗组患者在对照组治疗的基础上口服肝苏片，5片/次，3次/d。两组患者均连续治疗48周。观察两组患者的临床疗效，比较治疗前后两组患者肝功能、肝纤维化指标、健康调查简表（SF-36）评分、乙肝病毒的脱氧核糖核酸（HBV-DNA）定量水平和不良反应。结果 治疗后，对照组和治疗组临床有效率分别为70.00%、93.33%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、透明质酸酶（HA）、层粘连蛋白（LN）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者各指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的SF-36评分显著升高，HBV-DNA定量水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些指标改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，治疗组患者不良反应发生率为10.00%，显著低于对照组的36.67%，两组比较差异具有统计学意义（P<0.05）。结论 肝苏片联合聚乙二醇化干扰素α-2a注射液治疗慢性乙型肝炎的临床疗效显著、不良反应发生率低，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Gansu Tablets combined with Peginterferon α-2a Solution for injection in treatment of chronic viral hepatitis B. Methods Patients (60 cases) with chronic viral hepatitis B in Ledong People's Hospital from June 2014 to June 2016 were randomly divided into control (30 cases) and treatment (30 cases). Patients in the control group were hypodermic buttock injection administered with Peginterferon α-2a Solution for injection, 180 μg/time, once weekly. Patients in the treatment group were po administered with Gansu Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 48 weeks. After treatment, the clinical efficacy was evaluated, and the liver function indexes, liver fibrosis indexes, SF-36 scores, HBV-DNA quantitative levels, and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 70.00%, which was significantly lower than 93.33% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the levels of ALT, AST, HA, and LN in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the SF-36 scores in two groups were significantly increased, but the HBV-DNA levels were decreased, and the difference was statistically significant in the same group (P < 0.05). And these observation indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 10.00%, which was significantly lower than 36.67% in the control group, with significant difference between two groups (P < 0.05). Conclusion Gansu tablets combined with Peginterferon α-2a Solution for injection has significant clinical efficacy in the treatment of chronic viral hepatitis B with lower adverse reactions incidence, which has a certain clinical application value.